Search research articles
Contact Us
Filters
Showing results (91-100 of 121) with videos related to
Page
of 13
Sort By:
British Journal of Cancer
|
July 7, 2017
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma
A J Zurita, R C Gagnon, Y Liu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2018
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
A J Armstrong, P Lin, C S Higano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)
M E Gore, J Bellmunt, T Eisen, et al.
ESMO Open
|
May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy
A Bamias, A S Merseburger, Y Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL
J N Graff, G Baciarello, A J Armstrong, et al.
ESMO Open
|
January 18, 2021
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
S Aeppli, M Schmaus, T Eisen, et al.
Clinical Chemistry
|
April 2, 1999
Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer
L Thomas, H Leyh, M Marberger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 16, 2012
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
C N Sternberg, A Molina, S North, et al.
Anticancer Research
|
November 2, 2010
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey
A Mancuso, S Sacchetta, P C Saletti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2001
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924
C N Sternberg, P H de Mulder, J H Schornagel, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 121) with videos related to
Sort By:
Page
of 13
British Journal of Cancer
|
July 7, 2017
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma
A J Zurita, R C Gagnon, Y Liu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2018
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
A J Armstrong, P Lin, C S Higano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)
M E Gore, J Bellmunt, T Eisen, et al.
ESMO Open
|
May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy
A Bamias, A S Merseburger, Y Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL
J N Graff, G Baciarello, A J Armstrong, et al.
ESMO Open
|
January 18, 2021
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
S Aeppli, M Schmaus, T Eisen, et al.
Clinical Chemistry
|
April 2, 1999
Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer
L Thomas, H Leyh, M Marberger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 16, 2012
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
C N Sternberg, A Molina, S North, et al.
Anticancer Research
|
November 2, 2010
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey
A Mancuso, S Sacchetta, P C Saletti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2001
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924
C N Sternberg, P H de Mulder, J H Schornagel, et al.
Page
of 13